Recently, we investigated the circulating levels of GP88 in the serum of prostate cancer patients and showed that all PCa patients and particularly younger PCa patients with a low serum GP88 level had a significantly better overall survival compared with that of patients with higher serum GP88 levels [19]. Here, GRN is linked to prostate carcinoma.